In the next issue, we will check in with the FDA’s Priority review programme for pediatric rare diseases and how its entry into the ‘sunsetting’ phase can affect drug development efforts. We will also explore the nascent research behind in utero treatments for genetic disorders.
EDITORIAL
Editor |Manasi Vaidya
Deputy Editor | Ross Law
Writers | Robert Barrie, Abigail Beaney, Frankie Fattorini, Jenna Philpott
Graphic Designers | Anett Arc, Noemi Balint, Will Ingham, Miriam Garofalo
ADVERTISING
Sales Manager | Tom McCormick
+44 207 8669440
Copyright 2025 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.